Moreover, we have also demonstrated that over-expression and inhibition of miR-514a, not only leads to altered NF1 protein expression, but also contributes to altered BRAFi sensitivity in vitro. Studies of sequential biopsies taken during response and later at recurrence may reveal that miR-514a does indeed play a key role in the resistance mechanisms observed in melanoma patients undergoing targeted therapy with the common BRAF inhibitor (PLX4032). Here, NF1 is linked to melanoma.